404
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Piroxicam cocrystals with phenolic coformers: preparation, characterization, and dissolution properties

, , &
Pages 199-210 | Received 05 Nov 2017, Accepted 17 Mar 2018, Published online: 04 Apr 2018

References

  • Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML, Choudhury AR, Desiraju GR, Dikundwar AG, Dubey R, Duggirala N. 2012. Polymorphs, salts, and cocrystals: what’s in a name? Cryst Growth Des. 12:2147–2152.
  • Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12:413–420.
  • Arenas-García JI, Herrera-Ruiz D, Morales-Rojas H, Höpfl H. 2017. Interrelation of the dissolution behavior and solid-state features of acetazolamide cocrystals. Eur J Pharm Sci. 96:299–308.
  • Babu NJ, Nangia A. 2011. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des. 11:2662–2679.
  • Banerjee R, Bhatt PM, Ravindra NV, Desiraju GR. 2005. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Cryst Growth Des. 5:2299–2309.
  • Barzegar-Jalali M, Maleki N, Garjani A, Khandar A, Haji-Hosseinloo M, Jabbari R, Dastmalchi S. 2002. Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. Drug Dev Ind Pharm. 28:681–686.
  • Betigeri S, Thakur A, Shukla R, Raghavan K. 2008. Effect of polymer additives on the transformation of BMS-566394 anhydrate to the dihydrate form. Pharm Res. 25:1043–1051.
  • Bolla G, Sanphui P, Nangia A. 2013. Solubility advantage of tenoxicam phenolic cocrystals compared to salts. Cryst Growth Des. 13:1988–2003.
  • Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc. 126:13335–13342.
  • Childs SL, Hardcastle KI. 2007. Cocrystals of piroxicam with carboxylic acids. Cryst Growth Des. 7:1291–1304.
  • Gomes DJ, de Souza NC, Silva JR. 2013. Using a monocular optical microscope to assemble a wetting contact angle analyser. Measurement. 46:3623–3627.
  • Good DJ, Rodri´guez-Hornedo N. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des. 9:2252–2264.
  • Greco K, Bogner R. 2012. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. J Pharm Sci. 101:2996–3018.
  • Gwak H-S, Choi J-S, Choi H-K. 2005. Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int J Pharm. 297:156–161.
  • Karki S, Friščić T, Fábián L, Laity PR, Day GM, Jones W. 2009. Improving mechanical properties of crystalline solids by cocrystal formation: new compressible forms of paracetamol. Adv Mater. 21:3905–3909.
  • Khan T, Ranjan R, Dogra Y, Pandya SM, Shafi H, Singh S, Yadav PN, Misra A. 2016. Intranasal eutectic powder of zolmitriptan with enhanced bioavailability in the rat brain. Mol Pharm. 13:3234–3240.
  • Kirchmeyer W, Wyttenbach N, Alsenz J, Kuentz M. 2015. Influence of excipients on solvent-mediated hydrate formation of piroxicam studied by dynamic imaging and fractal analysis. Cryst Growth Des. 15:5002–5010.
  • Kogermann K, Penkina A, Predbannikova K, Jeeger K, Veski P, Rantanen J, Naelapää K. 2013. Dissolution testing of amorphous solid dispersions. Int J Pharm. 444:40–46.
  • Kumar SS, Nangia A. 2014. A solubility comparison of neutral and zwitterionic polymorphs. Cryst Growth Des. 14:1865–1881.
  • Lazghab M, Saleh K, Pezron I, Guigon P, Komunjer L. 2005. Wettability assessment of finely divided solids. Powder Technol. 157:79–91.
  • Liu X, Lu M, Guo Z, Huang L, Feng X, Wu C. 2012. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res. 29:806–817.
  • Lu E, Rodríguez-Hornedo N, Suryanarayanan R. 2008. A rapid thermal method for cocrystal screening. CrystEngComm. 10:665–668.
  • Lu Y, Tang N, Lian R, Qi J, Wu W. 2014. Understanding the relationship between wettability and dissolution of solid dispersion. Int J Pharm. 465:25–31.
  • Lust A, Laidmäe I, Palo M, Meos A, Aaltonen J, Veski P, Heinämäki J, Kogermann K. 2013. Solid-state dependent dissolution and oral bioavailability of piroxicam in rats. Eur J Pharm Sci. 48:47–54.
  • Manin AN, Voronin AP, Drozd KV, Manin NG, Bauer-Brandl A, Perlovich GL. 2014. Cocrystal screening of hydroxybenzamides with benzoic acid derivatives: a comparative study of thermal and solution-based methods. Eur J Pharm Sci. 65:56–64.
  • Mosharraf M, Nyström C. 2003. Apparent solubility of drugs in partially crystalline systems. Drug Dev Ind Pharm. 29:603–622.
  • Paaver U, Lust A, Mirza S, Rantanen J, Veski P, Heinämäki J, Kogermann K. 2012. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms. Int J Pharm. 431:111–119.
  • Patel JR, Carlton RA, Needham TE, Chichester CO, Vogt FG. 2012. Preparation, structural analysis, and properties of tenoxicam cocrystals. Int J Pharm. 436:685–706.
  • Rahman Z, Agarabi C, Zidan AS, Khan SR, Khan MA. 2011. Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide. AAPS PharmSciTech. 12:693–704.
  • Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB. 2007. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential. Mol Pharm. 4:386–400.
  • Sauceau M, Rodier E, Fages J. 2008. Preparation of inclusion complex of piroxicam with cyclodextrin by using supercritical carbon dioxide. J Supercrit Fluids. 47:326–332.
  • Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 9:2950–2967.
  • Shayanfar A, Asadpour-Zeynali K, Jouyban A. 2013. Solubility and dissolution rate of a carbamazepine–cinnamic acid cocrystal. J Mol Liq. 187:171–176.
  • Sheth AR, Zhou D, Muller FX, Grant DJ. 2004. Dehydration kinetics of piroxicam monohydrate and relationship to lattice energy and structure. J Pharm Sci. 93:3013–3026.
  • Shiraki K, Takata N, Takano R, Hayashi Y, Terada K. 2008. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res. 25:2581–2592.
  • Sowa M, Ślepokura K, Matczak-Jon E. 2014. Improving solubility of fisetin by cocrystallization. CrystEngComm. 16:10592–10601.
  • Stepanovs D, Jure M, Kuleshova LN, Hofmann DW, Mishnev A. 2015. Cocrystals of pentoxifylline: in silico and experimental screening. Cryst Growth Des. 15:3652–3660.
  • Swanepoel E, Liebenberg W, De Villiers MM, Dekker TG. 2000. Dissolution properties of piroxicam powders and capsules as a function of particle size and the agglomeration of powders. Drug Dev Ind Pharm. 26:1067–1076.
  • Taddei P, Torreggiani A, Simoni R. 2001. Influence of environment on piroxicam polymorphism: vibrational spectroscopic study. Biopolymers. 62:68–78.
  • Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini M-A, Adibkia K, Nokhodchi A. 2007. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm. 33:45–56.
  • Vrečer F, Vrbinc M, Meden A. 2003. Characterization of piroxicam crystal modifications. Int J Pharm. 256:3–15.
  • Wales C, Thomas LH, Wilson CC. 2012. Tautomerisation and polymorphism in molecular complexes of piroxicam with mono-substituted benzoic acids. CrystEngComm. 14:7264–7274.
  • Wang Z-Z, Chen J-M, Lu T-B. 2012. Enhancing the hygroscopic stability of S-oxiracetam via pharmaceutical cocrystals. Cryst Growth Des. 12:4562–4566.
  • Weyna DR, Cheney ML, Shan N, Hanna M, Zaworotko MJ, Sava V, Song S, Sanchez-Ramos JR. 2012. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. Mol Pharm. 9:2094–2102.
  • Yalkowsky SH, He Y, Jain P. 2016. Handbook of aqueous solubility data. Boca Raton (FL): CRC Press.
  • Yamashita H, Hirakura Y, Yuda M, Terada K. 2014. Coformer screening using thermal analysis based on binary phase diagrams. Pharm Res. 31:1946–1957.
  • Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. 2010. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 12:263–271.
  • Zhou Z, Chan HM, Sung HH-Y, Tong HH, Zheng Y. 2016. Identification of new cocrystal systems with stoichiometric diversity of salicylic acid using thermal methods. Pharm Res. 33:1030–1039.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.